EX-99.1 2 tm2133109d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

Zepp Health Corporation Reports Third Quarter 2021 Unaudited Financial Results

 

BEIJING, November 16, 2021 /PRNewswire/ -- Zepp Health Corporation (“Zepp” or the “Company”) (NYSE: ZEPP) today reported revenue of RMB1.6 billion (US$249.3 million); GAAP diluted net income per share of RMB0.19 (US$0.03); and GAAP diluted net income per ADS of RMB0.74 (US$0.11) for the third quarter ended September 30, 2021. Each ADS represents four (4) Class A ordinary shares.

 

“Despite global supply chain and chip shortage challenges affecting many companies, we are pleased to meet our guidance range for the third quarter of 2021,” said Wang Huang, Chairman and CEO of Zepp Health. “Even without any new product launches, unit shipment volumes of Amazfit and Zepp branded products increased 89% year-over-year, demonstrating continuing global expansion of our brands. We began the fourth quarter with new technology and products, including our new OS for independent apps and the launch of the next generation 3 of our best-selling GT series watch line.”

 

“Today, our board approved a $20 million share repurchase program.” Mr. Huang added, “The Share Repurchase Program is well aligned with our commitment to maximizing value for all of our stakeholders and reflects the Company's confidence in its sustainable growth and long-term strategy, supported by the strong balance sheet and cash position.”

 

Chief Financial Officer, Leon Deng, added “In addition to the strong growth of the Company’s own branded products, third quarter topline performance reflected the different timing for the launch of Xiaomi’s new Mi Band in the second quarter this year, as well as impacts of supply chain slowdowns and chip shortages. Despite these challenges, we successfully managed to continue our expense control, which reduced total operating expenses by 31.2%.”

 

Third Quarter 2021 Financial Summary

 

   For the Three Months Ended   For the Nine Months Ended 
GAAP in millions, except for percentages and per share/ADS amounts 

Sept. 30,

2021

  

Sept. 30,

20201

  

Sept. 30,

2021

  

Sept. 30,

20201

 
Revenue RMB   1,606.1    2,235.1    4,588.5    4,460.8 
Revenue US$   249.3    329.2    712.1    657.0 
Gross Margin   20.2%   20.6%   21.5%   21.5%
Net income attributable to Zepp Health Corporation RMB   49.3    81.1    101.5    113.5 
Adjusted net income attributable to Zepp Health Corporation RMB2   65.5    120.8    168.9    165.5 
Diluted net income per share RMB   0.19    0.31    0.38    0.44 
Diluted net income per ADS US$   0.11    0.18    0.24    0.26 
Adjusted diluted net income per share RMB3   0.25    0.46    0.64    0.64 
Adjusted diluted net income per ADS US$   0.15    0.27    0.40    0.38 
Units Shipped   9.9    15.9    27.8    32.4 

 

 

1 The US$ numbers in 2020 are referenced with the prior 6-K disclosures,which translations from RMB to US$ are made at a rate of RMB6.7896 to US$1.00, the effective noon buying rate for September 30, 2020 as set forth in the H.10 statistical release of the Federal Reserve Board.

2Adjusted net income attributable to Zepp Health Corporation is a non-GAAP measure, which excludes share-based compensation expenses. See "Reconciliation of GAAP and Non-GAAP Results" at the end of this press release.

3 Adjusted diluted net income is the abbreviation of adjusted net income attributable to Zepp Health Corporation, which is a non-GAAP measure and excludes share-based compensation expenses attributable to Zepp Health Corporation, and is used as the numerator in computation of adjusted basic and diluted net income per ADS attributable to Zepp Health Corporation.

 

1 

 

 

Third Quarter 2021 Financial Results

 

Revenue

 

Total units shipped in the third quarter of 2021 decreased by 37.7% year-over-year to 9.9 million, compared with 15.9 million in the third quarter of 2020. This was driven by a 45.3% decrease in unit shipments of Xiaomi wearable products partially offset by a 88.9% increase in unit shippments of Amazfit and Zepp branded products.

 

Revenues for the third quarter of 2021 reached RMB1.61 billion (US$249.3 million), a decrease of 28.1% from the third quarter of 2020, primarily as a result of decrease in sales of Xiaomi werable products as compared with the same period in 2020, which was due to the different launch time of Mi Band 5 and 6. Meanwhile, the revenue from our self-branded products increased, primarily driven by the sales of the Company’s popular premium GT series, basic Bip and Pop models and rugged T-Rex.

 

Both sequential and year-over-year quarterly revenue changes can be affected by fluctuations in seasonal purchase patterns as well as by the timing of new product introductions.

 

Impact of COVID-19 on Our Business

 

The global impact of the COVID-19 pandemic continued in the third quarter 2021, primarily manifesting as parts and supply chain challenges globally. The market is experiencing shortages of electronic components and chips for different industries, affecting the supply and production cycle for the Company, as well. Zepp Health had increased inventories of some parts, but supply chain delays of certain parts for a month affected production of finished goods. The Company cannot predict the potential, if any, future negative impact on market conditions or the Company’s operations.

 

2 

 

 

Gross Margin

 

Gross margin in the third quarter of 2021 was 20.2%, compared with 20.6% in the same period of 2020. Gross margin and gross profit are affected by product mix as different products have different margin contributions. These changes can also be influenced by the stage of the product in its lifecycle, product iterations and new product introductions.

 

Research & Development

 

Research and development expense in the third quarter of 2021 was RMB108.7 million, decreasing 37.1% year-over year, and comprising 6.8% of revenue, versus 7.7% in the same period last year. This reflects effective expense control in R&D activities and compensation from government subsidy. The company optimized its integrated product development process to effectively develop new smart devices and promoted its open platform ZEPP OS to welcome more outside developers to upload their apps and programs on the smart watches.

 

Sales & Marketing

 

Sales and Marketing expense in the third quarter of 2021 was RMB90.7 million, decreasing 21.5% year-over-year, and comprising 5.6% of revenue, compared with 5.2% of revenue in the same period in 2020. The decrease was due to effective expense control on marketing expenses while balancing investments to expand sales channels and markets around the world.

 

General & Administrative

 

General and Administrative expense was RMB61.9 million in the third quarter of 2021, decreasing 32.0% year-over-year, and comprising 3.9% of revenue, compared with 4.1% in the same period in 2020. The decrease was primarily due to the vesting of share-based compensation.

 

Operating Expenses and Net Income

 

Total operating expenses for the third quarter of 2021 were RMB261.3 million, a decrease of RMB118.2 million from the same period in 2020, comprising 16.3% of revenue, compared with 17.0% in the third quarter of 2020.

 

Operating income for the third quarter of 2021 was RMB62.5 million, a decrease of 22.5% from RMB80.6 million for the same period in 2020.

 

Net income attributable to Zepp Health Corporation for the third quarter of 2021 was RMB49.3 million, compared with RMB81.1 million in the third quarter of 2020.

 

3 

 

 

Liquidity and Capital Resources

 

As of September 30, 2021, the Company had cash and cash equivalents of RMB1,229.3 million (US$190.8 million), compared with RMB2,273.3 million as of December 31, 2020.

 

Share Repurchase Program

 

The Company's board of directors has approved a share repurchase program whereby the Company is authorized to repurchase up to US$20 million worth of its shares (including in the form of American depositary shares) over the next 12 months.

 

The Company's proposed repurchases may be made from time to time in the open market at prevailing market prices, in privately negotiated transactions, in block trades and/or through other legally permissible means, depending on market conditions and in accordance with applicable rules and regulations. The Company's board of directors will review the share repurchase program periodically, and may authorize adjustment of its terms and size. The Company expects to fund the repurchases out of its existing cash balance.‎

 

Outlook

 

For the fourth quarter of 2021, the management of the Company currently expects:

 

-Net revenues to be between RMB1.75 billion and RMB2.0 billion, compared with RMB1.97 billion in the fourth quarter of 2020.

 

This outlook reflects continuing uncertainty pertaining to the potential affects of the COVID-19 pandemic on sales and on electronic component delays, as well as expected sales seasonality of both self-branded and Xiaomi products. It is based on the current market conditions and reflects the Company management’s current and preliminary estimates of market and operating conditions and customer demand, which are all subject to change.

 

Conference Call

 

The Company’s management will hold a conference call at 7:30 a.m. Eastern Standard Time on Tuesday, November 16, 2021 (8:30 p.m. Beijing Time on November 16, 2021) to discuss financial results and answer questions from investors and analysts. Listeners may access the call by dialing:

 

4 

 

 

US (Toll Free): +1-888-346-8982
   
International: +1-412-902-4272
   
Mainland China (Toll Free): 400-120-1203
   
Hong Kong (Toll Free): 800-905-945
   
Hong Kong: +852-3018-4992

 

Participants should dial-in at least 10 minutes before the scheduled start time and ask to be connected to the call for "Zepp Health Corporation."

 

Additionally, a live and archived webcast of the conference call will be available at https://ir.zepp.com/investor.

 

A telephone replay will be available one hour after the call until November 23, 2021 by dialing:

 

US Toll Free: +1-877-344-7529
International: +1-412-317-0088
Replay Passcode: 10161759

 

About Zepp Health Corporation (NYSE: ZEPP)

 

Zepp Health changed its name from Huami Corp. (HMI) on February 25, 2021 to emphasize its health focus with a name that resonates across languages and cultures globally. The company's mission continues to be connecting health with technology. Since its inception in 2013, Zepp Health has developed a platform of proprietary technology including AI chips, biometric sensors, and data algorithms, which drive a broadening line of smart health devices for consumers, and data analytics services for population health.  Zepp Health is one of the largest global developers of smart wearable health and consumer fitness devices, shipping 46 million units in 2020. Zepp Health Corp. is based in Hefei, China, with U.S. operations, Zepp Health USA, based in Cupertino, California.

 

Use of Non-GAAP Measures

 

We use adjusted net income, a non-GAAP financial measure, in evaluating our operating results and for financial and operational decision-making purposes. Adjusted net income represents net income excluding share-based compensation expenses, and such adjustment has no impact on income tax. Adjusted net income attributable to Zepp Health Corporation is a non-GAAP measure, which excludes share-based compensation expenses attributable to Zepp Health Corporation, and is used as the numerator in computation of adjusted net income per share and per ADS attributable to Zepp Health Corporation.

 

5 

 

 

We believe that adjusted net income and adjusted net income attributable to Zepp Health Corporation help identify underlying trends in our business that could otherwise be distorted by the effect of certain expenses that we include in net income and net income attributable to Zepp Health Corporation. We believe that adjusted net income and adjusted net income attributable to Zepp Health Corporation provides useful information about our operating results, enhances the overall understanding of our past performance and future prospects and allows for greater visibility with respect to key metrics used by our management in its financial and operational decision-making.

 

Adjusted net income and adjusted net income attributable to Zepp Health Corporation, should not be considered in isolation or construed as an alternative to net income, basic and diluted net income per share and per ADS attributable to Zepp Health Corporation. or any other measure of performance or as an indicator of our operating performance. Investors are encouraged to review the historical non-GAAP financial measures to the most directly comparable GAAP measures. Adjusted net income and adjusted net income attributable to ordinary shareholders, presented here may not be comparable to similarly titled measures presented by other companies. Other companies may calculate similarly titled measures differently, limiting their usefulness as comparative measures to our data. We encourage investors and others to review our financial information in its entirety and not rely on a single financial measure.

 

Exchange Rate

 

The Company’s business is primarily conducted in China and the significant majority of revenues generated are denominated in RMB. This announcement contains currency conversions of RMB amounts into US$ solely for the convenience of the reader. Unless otherwise noted, all translations from RMB to US$ are made at a rate of RMB6.4434 to US$1.00, the effective noon buying rate for September 30, 2021 as set forth in the H.10 statistical release of the Federal Reserve Board. No representation is made that the RMB amounts could have been, or could be, converted, realized or settled into US$ at that rate on September 30, 2021, or at any other rate.

 

Safe Harbor Statement

 

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Statements that are not historical facts, including statements about the Company's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: the cooperation with Xiaomi, the recognition of the Company's self-branded products; the Company's growth strategies; trends and competition in global wearable technology market; changes in the Company's revenues and certain cost or expense accounting policies; governmental policies relating to the Company's industry and general economic conditions in China and the global. Further information regarding these and other risks is included in the Company's filings with the United States Securities and Exchange Commission. All information provided in this press release and in the attachments is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.

 

6 

 

 

For investor and media inquiries, please contact:

 

In China: 

Zepp Health Corporation 

Grace Yujia Zhang 

Email: ir@zepp.com

 

The Piacente Group, Inc. 

Yang Song 

Tel: +86-10-6508-0677 

Email: zepp@tpg-ir.com

 

In the United States: 

Zepp Health Corporation

Brad Samson 

Tel: 1+714-955-3951 

Email: brad.samson@zepp-usa.com

 

7 

 

 

 

Zepp Health Corporation
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
(Amounts in thousands of Renminbi ("RMB") and U.S. dollars ("US$")
except for number of shares and per share data, or otherwise noted)

 

   As of December 31,   As of September 30, 
   2020   2021 
   RMB   RMB   US$ 
Assets               
Current assets:               
Cash and cash equivalents   2,273,349    1,229,273    190,780 
Restricted cash   2,401    298    46 
Term deposit   5,000    5,000    776 
Accounts receivable   298,038    415,626    64,504 
Amounts due from related parties, current   860,213    761,725    118,218 
Inventories, net   1,217,537    1,271,432    197,323 
Short-term investments   18,430    19,358    3,004 
Prepaid expenses and other current assets   152,898    204,425    31,726 
Total current assets   4,827,866    3,907,137    606,377 
                
Property, plant and equipment, net   124,619    142,810    22,164 
Intangible asset, net   145,213    138,570    21,506 
Goodwill   62,515    61,733    9,581 
Long-term investments   443,986    1,536,659    238,486 
Deferred tax assets   120,190    170,650    26,484 
Other non-current assets   28,165    20,101    3,120 
Non-current operating lease right-of-use assets   151,165    118,479    18,388 
Total assets   5,903,719    6,096,139    946,106 

 

8 

 

 

Zepp Health Corporation
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
(Amounts in thousands of Renminbi ("RMB") and U.S. dollars ("US$")
except for number of shares and per share data, or otherwise noted)

 

   As of December 31,   As of September 30, 
   2020   2021 
   RMB   RMB   US$ 
Liabilities               
Current liabilities:               
Accounts payable   1,951,335    1,330,946    206,560 
Advance from customers   42,502    45,039    6,990 
Amount due to related parties, current   11,185    62,481    9,697 
Accrued expenses and other current liabilities   252,275    189,993    29,486 
Income tax payables   27,706    38,703    6,007 
Short-term bank borrowings   504,671    458,000    71,080 
Total current liabilities   2,789,674    2,125,162    329,820 
Deferred tax liabilities   22,374    25,568    3,968 
Long-term borrowing   60,000    726,865    112,808 
Other non-current liabilities   185,168    229,670    35,644 
Non-current operating lease liabilities   116,245    82,699    12,835 
Total liabilities   3,173,461    3,189,964    495,075 

 

9 

 

 

Zepp Health Corporation  
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS  
(Amounts in thousands of Renminbi ("RMB") and U.S. dollars ("US$")  
except for number of shares and per share data, or otherwise noted)  

 

 
   As of December 31,   As of September 30, 
   2020   2021 
   RMB   RMB   US$ 
Equity               
Ordinary shares   157    159    25 
Additional paid-in capital   1,552,109    1,629,644    252,917 
Accumulated retained earnings   1,133,368    1,234,855    191,646 
Accumulated other comprehensive income   44,624    37,768    5,861 
Total Zepp Health Corporation shareholders' equity   2,730,258    2,902,426    450,449 
Noncontrolling interests   -    3,749    582 
Total equity   2,730,258    2,906,175    451,031 
Total liabilities and equity   5,903,719    6,096,139    946,106 

 

10 

 

 

Zepp Health Corporation  
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS  
(Amounts in thousands of Renminbi ("RMB") and U.S. dollars ("US$")  
except for number of shares and per share data, or otherwise noted)  

 

   For the Three Months Ended September 30, 
   2020   2021 
   RMB   RMB   US$ 
Revenues   2,235,093    1,606,057    249,256 
Cost of revenues   (1,775,017)   (1,282,308)   (199,011)
Gross profit   460,076    323,749    50,245 
Operating expenses:               
Selling and marketing   (115,617)   (90,703)   (14,077)
General and administrative   (90,987)   (61,908)   (9,608)
Research and development   (172,891)   (108,663)   (16,864)
Total operating expenses   379,495    261,274    40,549 
Operating income   80,581    62,475    9,696 
Other income and expenses:               
Interest income   10,330    3,573    555 
Interest expense   (7,539)   (13,490)   (2,094)
Other income, net   1,785    1,742    270 
Gain from fair value change of long-term investment   3,304    -    - 
Income before income tax and income from equity method investment   88,461    54,300    8,427 
Income tax expenses   (8,437)   (6,229)   (967)
Income before loss from equity method investments   80,024    48,071    7,460 
Net income from equity method investments   2,472    996    155 
Net income   82,496    49,067    7,615 
Less: Net income/(loss) attributable to noncontrolling interest   1,422    (278)   (43)
Net income attributable to Zepp Health Corporation   81,074    49,345    7,658 
Net income per share attributable to Zepp Health Corporation               
                
Basic income per ordinary share   0.33    0.20    0.03 
Diluted income per ordinary share   0.31    0.19    0.03 
                
Net income per ADS (4 ordinary shares equal to 1 ADS)               
                
ADS – basic   1.30    0.78    0.12 
ADS – diluted   1.24    0.74    0.11 
                
Weighted average number of shares used in computing net income per share               

Ordinary share – basic

   248,748,630    252,495,778    252,495,778 
Ordinary share – diluted   260,829,357    266,301,240    266,301,240 

 

11 

 

 

Zepp Health Corporation
Reconciliation of GAAP and Non-GAAP Results
(Amounts in thousands of Renminbi ("RMB") and U.S. dollars ("US$")
except for number of shares and per share data, or otherwise noted)

 

   For the Three Months Ended September 30, 2021 
   2020   2021 
   RMB   RMB   US$ 
             
Net income attributable to Zepp Health Corporation   81,074    49,345    7,658 
Share-based compensation expenses   39,723    16,131    2,503 
Adjusted net income attributable to Zepp Health Corporation 2   120,797    65,476    10,161 
                
Adjusted net income per share attributable to Zepp Health Corporation               
Adjusted basic income per ordinary share   0.49    0.26    0.04 
Adjusted diluted income per ordinary share   0.46    0.25    0.04 
                
Adjusted net income per ADS (4 ordinary shares equal to 1 ADS)               
ADS – basic   1.94    1.04    0.16 
ADS – diluted   1.85    0.98    0.15 
                
Weighted average number of shares used in computing adjusted net income per share               
Ordinary share – basic   248,748,630    252,495,778    252,495,778 
Ordinary share – diluted   260,829,357    266,301,240    266,301,240 
                
Share-based compensation expenses included are follows:               
Selling and marketing   556    291    45 
General and administrative   21,033    9,036    1,402 
Research and development   18,134    6,804    1,056 
Total   39,723    16,131    2,503 

 

12 

 

 

Zepp Health Corporation
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Amounts in thousands of Renminbi ("RMB") and U.S. dollars ("US$")
except for number of shares and per share data, or otherwise noted)

 

   For the Nine Months Ended September 30, 
   2020   2021 
   RMB   RMB   US$ 
Revenues   4,460,828    4,588,461    712,118 
Cost of revenues   (3,502,809)   (3,603,471)   (559,250)
Gross profit   958,019    984,990    152,868 
Operating expenses:               
Selling and marketing   (241,802)   (286,176)   (44,414)
General and administrative   (197,293)   (193,641)   (30,053)
Research and development   (408,434)   (421,297)   (65,384)
Total operating expenses   847,529    901,114    139,851 
Operating income   110,490    83,876    13,017 
Other income and expenses:               
Investment income   -    13,507    2,096 
Interest income   31,668    13,826    2,146 
Interest expense   (16,312)   (30,480)   (4,730)
Other income, net   2,540    4,027    625 
Gain from fair value change of long-term investment   4,597    -    - 
Income before income tax and income from equity method investment   132,983    84,756    13,154 
Income tax expenses   (12,956)   (10,238)   (1,589)
Income before loss from equity method investments   120,027    74,518    11,565 
Net income/(loss) from equity method investments   (5,471)   26,289    4,080 
Net income   114,556    100,807    15,645 
Less: Net income/(loss) attributable to noncontrolling interest   1,007    (681)   (106)
Net income attributable to Zepp Health Corporation   113,549    101,488    15,751 
Net income per share attributable to Zepp Health Corporation               
                
Basic income per ordinary share   0.46    0.40    0.06 
Diluted income per ordinary share   0.44    0.38    0.06 
                
Net income per ADS (4 ordinary shares equal to 1 ADS)               
                
ADS – basic   1.83    1.61    0.25 
ADS – diluted   1.75    1.54    0.24 
                
Weighted average number of shares used in computing net income per share               

Ordinary share – basic

   248,080,549    251,707,456    251,707,456 
Ordinary share – diluted   259,723,569    264,369,709    264,369,709 

 

13 

 

 

Zepp Health Corporation
Reconciliation of GAAP and Non-GAAP Results
(Amounts in thousands of Renminbi ("RMB") and U.S. dollars ("US$")
except for number of shares and per share data, or otherwise noted)

 

   For the Nine Months Ended September 30, 
   2020   2021 
   RMB   RMB   US$ 
Net income attributable to Zepp Health Corporation   113,549    101,488    15,751 
Share-based compensation expenses   51,936    67,431    10,465 
Adjusted net income attributable to Zepp Health Corporation 2   165,485    168,919    26,216 
                
Adjusted net income per share attributable to Zepp Health Corporation               
Adjusted basic income per ordinary share   0.67    0.67    0.10 
Adjusted diluted income per ordinary share   0.64    0.64    0.10 
                
Adjusted net income per ADS (4 ordinary shares equal to 1 ADS)               
ADS – basic   2.67    2.68    0.42 
ADS – diluted   2.55    2.56    0.40 
                
Weighted average number of shares used in computing adjusted net income per share               
Ordinary share – basic   248,080,549    251,707,456    251,707,456 
Ordinary share – diluted   259,723,569    264,369,709    264,369,709 
                
Share-based compensation expenses included are follows:               
Cost of revenues   (54)   -    - 
Selling and marketing   1,820    7,311    1,135 
General and administrative   28,963    23,257    3,609 
Research and development   21,207    36,863    5,721 
Total   51,936    67,431    10,465 

 

14